Topic

Articles

ATMPS Ltd has been granted a patent from the United States Patent and Trademark Office for the use of its Hataali blockchain technology used in personalized medicines.

ATMPS Ltd Wins US Patent for the Use of Blockchain in Advanced Medicinal Therapy Products

Stanley Capital has announced the acquisition of MyMeds&Me by its portfolio company Drug Safety and Pharmacovigilance Services Solutions. 

Stanley Capital-Backed Portfolio Company DSS Acquires MyMeds&Me

Mike Hennessy Jr. is the President and CEO of 

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.

Major League Moves

 Washington Editor, jillwechsler7@gmail.com.

Consumer advocates continue to press for initiatives to lower drug prices by revising or reducing patent protections.

Patent Rights Battles Escalate as Debate over Drug Costs and Access Drags On

Mark White, PhD, is the associate director of Biopharma Product Marketing at Bio-Rad.

Marwan Alsarraj is the Biopharma Segment manager at Bio-Rad.

CAR-T cell therapy development is a complex process that requires standardization.

Assessing the Quality of CAR-T Cells Using ddPCR

The US Congress approved a federal spending package that increases funding for a range of programs to advance health and medicine.


Federal Budget Bill Boosts FDA Funding, Supports New Research Institute

Biotech companies and medical product manufacturers have condemned the invasion of Ukraine, while also looking to maintain supplies of essential medicines.

Ukraine Invasion Challenges Biopharma Research and Operations

Novartis will pay Voyager up to $1.75 billion for access to Voyager’s novel Tracer AAV capsids for potential use with three CNS targets.

Voyager Therapeutics Announces License Agreement with Novartis Worth Up to $1.75 Billion

Feliza Mirasol is the science editor for 

A rise in investments and funding into regenerative medicines projects has helped to advance a rich clinical pipeline. 

Regenerative Medicines Development Activity Spikes on Back of Focused Investments

A consortium of nine development partners will support Biovac's expansion of its existing vaccine manufacturing plant capacity, while Biovac itself aims to raise funds to boost increased vaccine manufacturing capacity across Africa.

BioBusiness